Atıf İçin Kopyala
Aras Y., Erguven M., Aktas E., Yazihan N., Bilir A.
NEUROLOGICAL RESEARCH, cilt.38, sa.9, ss.766-774, 2016 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
38
Sayı:
9
-
Basım Tarihi:
2016
-
Doi Numarası:
10.1080/01616412.2016.1203096
-
Dergi Adı:
NEUROLOGICAL RESEARCH
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.766-774
-
Anahtar Kelimeler:
Imatinib mesylate, Lithium chloride, Midkine, Glioblastoma, Antagonism, BETA-CATENIN, MIDKINE, INHIBITION, EXPRESSION, AUTOPHAGY, ACTIVATION, MECHANISMS, ARREST
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro.